![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ARSK |
Gene summary for ARSK |
![]() |
Gene information | Species | Human | Gene symbol | ARSK | Gene ID | 153642 |
Gene name | arylsulfatase family member K | |
Gene Alias | TSULF | |
Cytomap | 5q15 | |
Gene Type | protein-coding | GO ID | GO:0000323 | UniProtAcc | Q6UWY0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
153642 | ARSK | HCC1_Meng | Human | Liver | HCC | 1.75e-29 | -1.78e-05 | 0.0246 |
153642 | ARSK | HCC1 | Human | Liver | HCC | 1.42e-09 | 2.67e+00 | 0.5336 |
153642 | ARSK | HCC2 | Human | Liver | HCC | 1.03e-16 | 2.34e+00 | 0.5341 |
153642 | ARSK | HCC5 | Human | Liver | HCC | 4.51e-05 | 6.40e-01 | 0.4932 |
153642 | ARSK | S014 | Human | Liver | HCC | 2.71e-03 | 1.84e-01 | 0.2254 |
153642 | ARSK | S015 | Human | Liver | HCC | 1.87e-02 | 1.94e-01 | 0.2375 |
153642 | ARSK | S016 | Human | Liver | HCC | 1.24e-06 | 2.24e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARSK | SNV | Missense_Mutation | c.1385C>A | p.Ser462Tyr | p.S462Y | Q6UWY0 | protein_coding | tolerated(0.38) | benign(0.324) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD | |
ARSK | SNV | Missense_Mutation | novel | c.895N>A | p.Gln299Lys | p.Q299K | Q6UWY0 | protein_coding | tolerated(0.15) | benign(0.003) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
ARSK | SNV | Missense_Mutation | novel | c.1565N>T | p.Ala522Val | p.A522V | Q6UWY0 | protein_coding | deleterious(0.01) | possibly_damaging(0.796) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
ARSK | SNV | Missense_Mutation | novel | c.421C>T | p.Arg141Cys | p.R141C | Q6UWY0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ARSK | SNV | Missense_Mutation | novel | c.1093C>A | p.Leu365Ile | p.L365I | Q6UWY0 | protein_coding | deleterious(0.01) | probably_damaging(0.91) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ARSK | SNV | Missense_Mutation | rs780890433 | c.493N>T | p.Arg165Cys | p.R165C | Q6UWY0 | protein_coding | deleterious(0.01) | possibly_damaging(0.564) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
ARSK | SNV | Missense_Mutation | novel | c.524N>T | p.Arg175Met | p.R175M | Q6UWY0 | protein_coding | tolerated(0.1) | benign(0.262) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
ARSK | SNV | Missense_Mutation | novel | c.499A>G | p.Arg167Gly | p.R167G | Q6UWY0 | protein_coding | tolerated(0.22) | benign(0.034) | TCGA-BG-A221-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARSK | SNV | Missense_Mutation | novel | c.497A>G | p.Asn166Ser | p.N166S | Q6UWY0 | protein_coding | tolerated(0.19) | benign(0.029) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARSK | SNV | Missense_Mutation | c.572C>T | p.Ala191Val | p.A191V | Q6UWY0 | protein_coding | deleterious(0.03) | possibly_damaging(0.575) | TCGA-D1-A177-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |